Advertisement
Advertisement
BCYC
Bicycle Therapeutics plc - ADR
5.64
USDSponsored
+0.33
+6.14%
Feb 06, 15:59 UTC -5
Closed
After-Market
5.66
+0.02
+0.43%
BCYC Earnings Reports
Positive Surprise Ratio
BCYC beat 12 of 26 last estimates.
46%
Next Report
Date of Next Report
Feb 23, 2026
Estimate for Q4 25 (Revenue/ EPS)
$7.22M
/-$0.95
Implied change from Q3 25 (Revenue/ EPS)
-38.49%
/+11.76%
Implied change from Q4 24 (Revenue/ EPS)
+94.65%
/+15.85%
Bicycle Therapeutics plc - ADR earnings per share and revenue
On Oct 30, 2025, BCYC reported earnings of -0.85 USD per share (EPS) for Q3 25, beating the estimate of -1.09 USD, resulting in a 22.68% surprise. Revenue reached 11.73 million, compared to an expected 7.48 million, with a 56.88% difference. The market reacted with a +7.09% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 16 analysts forecast an EPS of -0.95 USD, with revenue projected to reach 7.22 million USD, implying an increase of 11.76% EPS, and decrease of -38.49% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were Bicycle Therapeutics plc - ADR's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Bicycle Therapeutics plc - ADR reported EPS of -$0.85, beating estimates by 22.68%, and revenue of $11.73M, 56.88% above expectations.
How did the market react to Bicycle Therapeutics plc - ADR's Q3 2025 earnings?
The stock price moved up 7.09%, changed from $8.18 before the earnings release to $8.76 the day after.
When is Bicycle Therapeutics plc - ADR expected to report next?
The next earning report is scheduled for Feb 23, 2026.
What are the forecasts for Bicycle Therapeutics plc - ADR's next earnings report?
Based on 16
analysts, Bicycle Therapeutics plc - ADR is expected to report EPS of -$0.95 and revenue of $7.22M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement